Meeting
2013 ASCO Annual Meeting
CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
Authors
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA
F. Stephen Hodi , Asim Amin , Yvonne M. Saenger , Gregory K. Pennock , Troy H. Guthrie , April K. Salama , Lawrence E. Flaherty , Henry B. Koon , David H. Lawson , Montaser F. Shaheen , Agnes Balogh , Cyril Konto , Steven O'Day
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01673854
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS9103)
DOI
10.1200/jco.2013.31.15_suppl.tps9103
Abstract #
TPS9103
Poster Bd #
53H
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
First Author: Asim Amin
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2016 ASCO Annual Meeting
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).
First Author: Paolo Antonio Ascierto
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton